Circulating Small Extracellular Vesicles Involved in Systemic Regulation Respond to RGC Degeneration in Glaucoma.

Area of Science:

• Ophthalmology
• Neuroscience
• Biotechnology

Background:

• Glaucoma is a leading cause of irreversible blindness, characterized by retinal ganglion cell (RGC) degeneration.
• Early diagnosis and neuroprotection are crucial for managing glaucoma due to irreversible neurodegeneration.
• Small extracellular vesicles (sEVs) are emerging as potential biomarkers and therapeutics.

Purpose of the Study:

• To investigate the therapeutic potential of plasma-derived sEVs (PDEV) in glaucoma.
• To identify the role of PDEV-derived microRNAs (miRNAs) in RGC pathophysiology.
• To explore engineered sEVs for enhanced glaucoma treatment.

Main Methods:

• Intravitreal injection of PDEV from glaucoma patients into chronic ocular hypertension (COH) mice.
• Quantification of PDEV-miR-29s in glaucoma patients and correlation with visual field defects.
• In vivo and in vitro experiments using miR-29b-3p overexpression and engineered sEVs.

Main Results:

• PDEV from glaucoma patients ameliorated retinal degeneration in COH mice.
• PDEV-miR-29s were upregulated in glaucoma patients and linked to visual field defects.
• miR-29b-3p overexpression protected RGCs in COH mice and promoted neuronal differentiation.
• Engineered sEVs with miR-29b-3p showed enhanced RGC protection and neuronal differentiation.

Conclusions:

• Elevated PDEV-miR-29s suggest a systemic regulatory mechanism in glaucoma.
• PDEV-based strategies offer promising avenues for glaucoma diagnosis and neuroprotection.
• This research provides insights into novel therapeutic approaches for neurodegenerative diseases.